JPS6348870B2 - - Google Patents
Info
- Publication number
- JPS6348870B2 JPS6348870B2 JP60046700A JP4670085A JPS6348870B2 JP S6348870 B2 JPS6348870 B2 JP S6348870B2 JP 60046700 A JP60046700 A JP 60046700A JP 4670085 A JP4670085 A JP 4670085A JP S6348870 B2 JPS6348870 B2 JP S6348870B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- mercaptotetrazole
- solution
- thiol
- crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XOHZHMUQBFJTNH-UHFFFAOYSA-N 1-methyl-2h-tetrazole-5-thione Chemical compound CN1N=NN=C1S XOHZHMUQBFJTNH-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000002900 organolithium compounds Chemical class 0.000 claims description 2
- 150000007970 thio esters Chemical class 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- -1 tetrazole compounds Chemical class 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- UOTQEHLQKASWQO-UHFFFAOYSA-N 2-(5-sulfanylidene-2h-tetrazol-1-yl)acetic acid Chemical compound OC(=O)CN1N=NN=C1S UOTQEHLQKASWQO-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- JAAIPIWKKXCNOC-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-thiolate Chemical compound SC1=NN=NN1 JAAIPIWKKXCNOC-UHFFFAOYSA-N 0.000 description 2
- RDHBKRQOSVEWGC-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)butanoic acid Chemical compound CCC(C(O)=O)SC1=NN=NN1 RDHBKRQOSVEWGC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical compound CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 2
- LZIZWPKCGUKIGH-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C=1N=NNN=1 LZIZWPKCGUKIGH-UHFFFAOYSA-N 0.000 description 1
- ZAWYIVQSOZFTHM-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)decanoic acid Chemical compound CCCCCCCCC(C(O)=O)SC1=NN=NN1 ZAWYIVQSOZFTHM-UHFFFAOYSA-N 0.000 description 1
- PTNXHTWBYIQRQT-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)heptanoic acid Chemical compound CCCCCC(C(O)=O)SC1=NN=NN1 PTNXHTWBYIQRQT-UHFFFAOYSA-N 0.000 description 1
- MYNKWTVOTSWCSE-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)hexanoic acid Chemical compound CCCCC(C(O)=O)SC1=NN=NN1 MYNKWTVOTSWCSE-UHFFFAOYSA-N 0.000 description 1
- LESZCGLMDCLIHC-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)nonanoic acid Chemical compound CCCCCCCC(C(O)=O)SC1=NN=NN1 LESZCGLMDCLIHC-UHFFFAOYSA-N 0.000 description 1
- QPBAGFQPADYDBB-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)octanoic acid Chemical compound CCCCCCC(C(O)=O)SC1=NN=NN1 QPBAGFQPADYDBB-UHFFFAOYSA-N 0.000 description 1
- CTXRELZEQZUMNY-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)pentanoic acid Chemical compound CCCC(C(O)=O)SC1=NN=NN1 CTXRELZEQZUMNY-UHFFFAOYSA-N 0.000 description 1
- VBWYAKMJWHGBIV-UHFFFAOYSA-N 2-(2h-tetrazol-5-ylsulfanyl)propanoic acid Chemical compound OC(=O)C(C)SC1=NN=NN1 VBWYAKMJWHGBIV-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- UPTRONYNXNYITM-UHFFFAOYSA-N ethyl 3-isothiocyanatopropanoate Chemical compound CCOC(=O)CCN=C=S UPTRONYNXNYITM-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- ACMLBODZYHZSRU-UHFFFAOYSA-N sodium;2-(5-sulfanylidene-2h-tetrazol-1-yl)acetic acid Chemical compound [Na].[Na].OC(=O)CN1NN=NC1=S ACMLBODZYHZSRU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C265/00—Derivatives of isocyanic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
本発明は新規なテトラゾール化合物の製法に関
する。更に詳しくは本発明は式
(ただし式中nは1ないし9である)を有する
1―カルボキシアルキル―5―メルカプトテトラ
ゾール〔1―カルボキシアルキルテトラゾール―
5―チオールとも呼ぶ〕の製法に関する。
上記の式で表わされるテトラゾール化合物は新
規な抗菌剤である7―(アシルアミノ)―3―
(1―カルボキシアルキルテトラゾール―5―イ
ルチオメチル)―3―セフエム―4―カルボン酸
を製造するための反応試剤として有用である。こ
の新規な抗菌剤の製法は原特許出願(昭和50年特
許出願第106106号)の発明の主題であるが、該製
法は式
(ただし式中R1はアシルであり、R3はHまた
はメトキシであり、nは1から9までの整数であ
る)の化合物、あるいはそのエステルまたは毒性
のない医薬として使用可能な塩の製法において、
式
(ただし式中R1はHまたはアシルであり、R3
は上に定義したとおりである)の化合物、あるい
はその塩または容易に加水分解可能なエステルを
式
(ただし式中nは1ないし9である)の化合物
と反応させ、かつR1がHである時には、得られ
た化合物を式
R1−X
(ただし式中Xはハロゲン化物またはその官能
均等物であり、R1はアシルであり、それは、ア
シル基が遊離のアミノまたはヒドロキシルを含む
時には、該基は常用の保護基によつて閉塞されて
おり、次に除去されて式の化合物を得る)のア
シル化剤で処理し、かつ、所望の場合には、得ら
れた式の化合物の遊離の酸、塩または容易に加
水分解可能なエステルにおいて該得られた化合物
を対応するそのエステルまたは毒性のない医薬と
して使用可能な塩に変換し、かつ、所望の場合に
は、得られた式の化合物の塩または容易に加水
分解可能なエステルにおいて該化合物を対応する
式の遊離の酸に変換することから成る方法、と
要約することができる。
本発明の第1の発明によれば、式
の化合物の製法において、
(a) 1―メチル―5―メルカプトテトラゾールを
有機リチウム化合物で処理して対応するリチオ
誘導体を得;
(b) リチオ誘導体を二酸化炭素で処理し、次にこ
れを加水分解して所望の製品を製造することを
特徴とする方法、が提供される。
また、本発明の第2の発明によれば、式
(ただし式中nは1ないし9である)の化合物
の製法において、
(a) 式
(ただし式中nは上に定義したとおりであ
り、R100は1ないし6個の炭素原子のアルキ
ル、フエニル、フエニルアルキルまたは置換フ
エニルまたはフエニルアルキルである)のイソ
チオシアネートをアジ化ナトリウムで処理して
式
(ただし式中nおよびR100は上に定義したと
おりである)のチオールエステルを得;
(b) チオールエステルを加水分解して所望のチオ
ール酸を製造する
ことを特徴とする方法、が提供される。
実施例 1
1―カルボキシメチル―5―メルカプトテトラ
ゾール
−7℃のエーテル150ml中の1―メチル―5―
メルカプトテトラゾール5g(0.043モル)の溶
液に、ヘキサン中の1.6M/lのn―ブチルリチ
ウム60ml(0.096モル)を窒素下で激しく撹拌し
ながら5分間にわたつて添加した。この混合物を
−5℃で1/2時間撹拌し、2時間にわたつて室温
(20℃)にまで加温した。この混合物に乾燥した
二酸化炭素25gを添加した。この混合物を更に2
時間撹拌した。白色沈澱を濾過によつて除き、エ
ーテルで洗浄し、そして50mlの水にとかした。
6N塩酸でこの溶液をPH2にまで酸性化し、酢酸
エチルで抽出した。酢酸エチルを水で洗い、60℃
(15mmHg)で蒸発させて白色固体を得た。この固
体を50mlのクロロホルムと共に還流加熱し、5℃
に冷却し、そして白色結晶沈澱を集めて56℃で24
時間真空乾燥した後、表記の目的化合物3.7gを
得た。
融点 167〜170℃
分析 C3H4N4O2S
計算値 C,22.50;H,2.52;N,34.98
実測値 C,22.69;H,2.69;N,36.66
NMR:DMSO,PPMδ;5.1,5.2(N−CH2 )
IR(KBr)cm-1;2400,3200(OH,SH);1730
(C=0)
実施例 2
a 1―メチル―5―メルカプトテトラゾールの
再結晶操作:
1 110gの1―メチル―5―メルカプトテト
ラゾールを350mlの沸騰水中スラリとする。
溶液に近いものが得られる。
2 この熱溶液(50〜60゜)を、1/4ないし1/3
インチの詰めた過助剤(「スーパーコル」)
を含有するブヒナー斗(11cmSS604号紙)
を通して真空によりすみやかに過する。フ
イルターパツドを50〜60℃のクロロホルム50
mlで洗浄し、これを液に加える。
3 液を約0〜6℃に冷却し、2時間0〜6
℃に保つ。生成した結晶を、0〜6℃におい
て過により集め、0〜6℃のクロロホルム
60mlで洗浄し、これを液に加える。結晶
(カツトA)を37〜45℃において18時間風乾
する。
4 回転真空エバポレーター(浴60℃)上約半
分の容量まで液を濃縮する。このスラリを
0〜6℃に冷却し、2時間0〜6℃に保つ。
結晶を0〜6℃において過により集め、0
〜6℃のクロロホルム40mlで洗浄し、これを
液に加える。結晶(カツトB)を37〜45℃
において18時間風乾する。結晶カツトAおよ
びBを混成して約65重量%の収量を得る。
5 工程4カツトBの液を工程4中記載した
ようにして2回再処理して更に15%の回収を
得ることができる。
b 1―カルボキシメチル―5―メルカプトテト
ラゾールのジ―ナトリウム塩の製造
操 作
1 撹拌機つき2リツトル3頚フラスコ中の実質
的に乾燥した純テトラヒドロフラン100mlを塩
―アセトン―氷浴中で約−10℃まで冷却する。
液面に乾燥窒素ガスを吹込む。
2 このテトラヒドロフランに乾燥窒素気流中撹
拌下にヘキサン中15.06%(1.6N)のブチルリ
チウム(フート・ミネラル・カンパニー)500
mlを10分間に亘つて添加する。この溶液に近い
ものを−5ないし−10℃に冷却する。
3 実質的に純粋な乾燥したテトラヒドロフラン
200mlに1―メチル―5―メルカプトテトラゾ
ール(上のようにして再結晶)46.4gを溶解す
る。濁つている場合にはこの溶液を過し、5
ないし10℃に冷却する。
4 ブチルリチウム溶液に撹拌下乾燥窒素気流中
工程3の冷却溶液を10分間に亘つて添加する。
温度は、−5℃ないし最高+10℃に保たなけれ
ばならない。沈澱が生成することがある。
5 この混合物を窒素気流中0℃ないし+10℃に
おいて0.5時間撹拌する。
6 無水炭酸ガスを、外温(0〜10℃)ないし+
20℃以下において15分間早い速度および早い撹
拌下に吹込む。
7 低湿度の場所で生成する白色沈澱を過によ
り適当に集める。沈澱をテトラヒドロフラン約
75mlで洗浄する。
8 水250ml(PH8.5〜9.5)にこの沈澱を溶解す
る。テトラヒドロフランの第二の層が存在して
いてよい。このものは、真空回転式エバポレー
ター(浴50℃)中除去することができる。
9 濃塩酸でこの水溶液をPH1.6〜2.0に調節す
る。
10 この酸水溶液を酢酸エチル250mlづつで2回
抽出する。各250mlの酢酸エチルを水100mlづつ
で逆抽出する。水抽出液を棄てる。酢酸エチル
抽出液(水層を含まない)を過し、混成す
る。
11 酢酸エチル抽出液を合して真空回転式エバポ
レーター(浴60℃)上濃縮乾固する。
12 フラスコ中の結晶をクロロホルム300mlと共
に2分間沸騰させる。熱スラリを加熱ブヒナー
斗(11cm―SS―604紙)を通して真空過す
る。結晶を50℃のクロロホルム約75mlで洗浄す
る。室温において約3時間結晶を風乾し、次に
約100〜200メツシユとする。
13 正確に工程12中記載されるようにしてこの
100〜200メツシユの結晶を処理する(熱クロロ
ホルムは未反応の1―メチル―5―メルカプト
テトラゾールの大部分を除去する)。収量:結
晶性1―カルボキシメチル―5―メルカプトテ
トラゾール約45ないし50g。これらの結晶は、
0.02ないし0.05モルの1―メチル―5―メルカ
プトテトラゾールを含有していてよい。
14 工程13の結晶を、室温において3〜5分間エ
チルエーテル250mlでスラリとする。この混合
物を過する。不溶物(0.5〜5%)は、次の
仮の構造の夾雑対称メルカプトテトラゾールケ
トンであるかもしれない:
注意:この化合物は、約205〜210℃において爆発
する。
15 工程14のエーテル液を、真空回転式エバポ
レーター(浴50℃)上蒸発乾固させる。約0.01
〜0.05モルの1―メチル―5―メルカプトテト
ラゾールを含有する結晶性1―カルボキシメチ
ル―5―メルカプトテトラゾール約42ないし48
gが回収される。
16 この結晶を無水エタノール420mlに溶解する
(約100mg/ml)。溶液を50〜60℃に加温する。
17 工程16の熱溶液に、イソプロパノール中41%
の2―エチルヘキサン酸ナトリウム(SEH)
310mlをきわめて早い撹拌下10分間に亘つて添
加する。結晶性沈澱が生成する。この混合物を
50〜60℃において20分間スラリにする。
18 加熱ブヒナー斗(11cm―SS―604号紙)を
通してこの混合物を熱時過する。結晶を50℃
のエタノール75mlで洗浄する。
19 工程18のエタノール湿結晶をエタノール200
〜300ml中スラリにする。スラリを200メツシユ
のふるいに通す。早い撹拌下このスラリを50〜
60℃に5分間加熱する(未反応の1―メチル―
5―メルカプトテトラゾールナトリウムは熱エ
タノールにきわめて可溶性である)。
20 加熱ブヒナー斗中11cm―SS―604号紙上50
〜60℃において結晶を集める。この結晶を75〜
100mlのエタノールで洗浄し、50〜60℃におい
て24〜48時間乾燥する。
収量:1―カルボキシメチル―5―メルカプトテ
トラゾールジ―ナトリウム(NMRにより
観察して1―メチル―5―メルカプトテト
ラゾールを含まない)40〜48g。
実施例 3
1―カルボキシエチルテトラゾール―5―チオ
ール
A 2―カルベトキシエチルイソチオシアネート
塩酸β―アラニンエチルエステル(93.6g)、
トリエチルアミン(123.5g)および塩化メチレ
ン(400ml)を混和し、−10℃に冷却した。温度を
約−10℃に保ちながら上の溶液にクロロホルム
150mlに溶解した二硫化炭素(46.5g)を2時間
の間に添加した。添加完了後、約10分間温度10℃
まで昇温させた。この溶液をふたたび−10℃に冷
却し、撹拌下40分間でクロロホルム60ml中クロロ
ギ酸66.9gを添加した。30分間温度を室温まで昇
温させ、ふたたび0℃に冷却した。0℃において
トリエチルアミン61.6gを更に添加し、次に溶液
を室温において3時間撹拌した。
この混合物を水で処理し、有機相を集め、2N
HCl250ml2回、NaHCO3250ml2回、次に水250
ml2回洗浄した。有機相をNa2SO4上乾燥し、溶
媒を真空下除去して油(所望の生成物であること
が見出された)93.7gを得た。IRおよびNMRス
ペクトルは構造と合致していた。
B 1―カルボキシエチルテトラゾール―5―チ
オール
アジ化ナトリウム(29.7g)を水400mlに溶解
し、窒素気流中60℃に加熱した。スケリソルブB
(本質的にn―ヘキサン)50mlに溶解した2―カ
ルボエトキシエチルイソチオシアネート(46.9
g)を加熱したアジ化ナトリウム溶液に添加し
た。この溶液を約70〜72℃において約150分間撹
拌し、次に氷浴中30℃に冷却した。PHが12になる
まで50%水酸化ナトリウム溶液を添加した。この
混合物を70℃において40分間加熱し、氷浴中15℃
に冷却した。濃HClを使用してPHを2に調節し、
次に酢酸エチル(150ml×4)で抽出した。酢酸
エチル抽出液を水洗し、硫酸ナトリウム上乾燥し
た。溶媒を真空蒸発させ、塩化メチレンからの結
晶として生成物を集めた。表題の生成物19.5gを
得た。
融点 147〜150℃
NMR:DMSO,PPMδ;2.9,t,2,
The present invention relates to a method for producing novel tetrazole compounds. More specifically, the present invention is based on the formula 1-carboxyalkyl-5-mercaptotetrazole [1-carboxyalkyltetrazole-
5-thiol]. The tetrazole compound represented by the above formula is a novel antibacterial agent, 7-(acylamino)-3-
It is useful as a reaction reagent for producing (1-carboxyalkyltetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid. The manufacturing method of this new antibacterial agent is the subject of the invention of the original patent application (Patent Application No. 106106 of 1975), but the manufacturing method is based on the formula (wherein R 1 is acyl, R 3 is H or methoxy, and n is an integer from 1 to 9), or its ester or non-toxic pharmaceutically usable salt. ,
formula (However, in the formula, R 1 is H or acyl, and R 3
is as defined above), or a salt or easily hydrolyzable ester thereof, with the formula (wherein n is 1 to 9) and when R 1 is H, the obtained compound is reacted with a compound of the formula R 1 -X (wherein X is a halide or a functional equivalent thereof). and R 1 is acyl, which means that when the acyl group contains a free amino or hydroxyl, the group is occluded by a conventional protecting group and then removed to yield a compound of formula) and, if desired, in the free acid, salt or easily hydrolysable ester of the compound of the formula obtained, in the form of the corresponding ester or toxic and, if desired, converting the resulting compound of the formula into a salt or easily hydrolyzable ester into the free acid of the corresponding formula. It can be summarized as a method consisting of: According to the first aspect of the present invention, the formula (a) Treating 1-methyl-5-mercaptotetrazole with an organolithium compound to obtain the corresponding lithio derivative; (b) Treating the lithio derivative with carbon dioxide, which is then hydrolyzed. A method of manufacturing a desired product is provided. Furthermore, according to the second aspect of the present invention, the formula (wherein n is 1 to 9) In the method for producing a compound of formula (a) (wherein n is as defined above and R 100 is alkyl, phenyl, phenylalkyl or substituted phenyl or phenylalkyl of 1 to 6 carbon atoms) with sodium azide. process and expression (b) hydrolyzing the thiol ester to produce the desired thiol acid. Ru. Example 1 1-carboxymethyl-5-mercaptotetrazole 1-Methyl-5- in 150 ml of ether at -7°C
To a solution of 5 g (0.043 mol) of mercaptotetrazole was added 60 ml (0.096 mol) of 1.6 M/l n-butyllithium in hexane under nitrogen and with vigorous stirring over a period of 5 minutes. The mixture was stirred at -5°C for 1/2 hour and warmed to room temperature (20°C) over 2 hours. To this mixture was added 25 g of dry carbon dioxide. Add 2 more of this mixture
Stir for hours. The white precipitate was removed by filtration, washed with ether and dissolved in 50ml of water.
The solution was acidified to PH2 with 6N hydrochloric acid and extracted with ethyl acetate. Wash ethyl acetate with water and heat at 60°C.
Evaporation at (15 mmHg) gave a white solid. This solid was heated to reflux with 50 ml of chloroform at 5°C.
Cool to 24°C and collect the white crystalline precipitate at 56°C.
After vacuum drying for an hour, 3.7 g of the title compound was obtained. Melting point 167-170℃ Analysis C 3 H 4 N 4 O 2 S Calculated value C, 22.50; H, 2.52; N, 34.98 Actual value C, 22.69; H, 2.69; N, 36.66 NMR: DMSO, PPMδ; 5.1, 5.2 (N-C H 2 ) IR (KBr) cm -1 ; 2400, 3200 (OH, SH); 1730
(C=0) Example 2 a Recrystallization operation of 1-methyl-5-mercaptotetrazole: 1 110 g of 1-methyl-5-mercaptotetrazole is slurried in 350 ml of boiling water.
You will get something close to a solution. 2 Add 1/4 to 1/3 of this hot solution (50 to 60°)
Inch-packed super-aid (“Supercol”)
Buchner To (11cmSS604 paper) containing
Immediately vacuum through. Filter pad in chloroform at 50-60℃ 50
ml and add this to the solution. 3 Cool the liquid to about 0-6℃ and keep it at 0-6℃ for 2 hours.
Keep at ℃. The formed crystals were collected by filtration at 0 to 6°C, and then added to chloroform at 0 to 6°C.
Wash with 60ml and add this to the solution. The crystals (cut A) are air-dried at 37-45°C for 18 hours. 4 Concentrate the liquid to about half the volume on a rotary vacuum evaporator (bath 60°C). Cool the slurry to 0-6°C and keep at 0-6°C for 2 hours.
The crystals were collected by filtration at 0-6°C and
Wash with 40 ml of chloroform at ~6°C and add this to the solution. Crystals (cut B) at 37-45℃
Air dry for 18 hours. Crystal cuts A and B are mixed to give a yield of about 65% by weight. 5 Step 4 Cut B liquor can be reprocessed twice as described in Step 4 to obtain an additional 15% recovery. b. Preparation of the di-sodium salt of 1-carboxymethyl-5-mercaptotetrazole Procedure 1: 100 ml of substantially dry pure tetrahydrofuran in a 2 liter 3-necked flask with a stirrer was dissolved in a salt-acetone-ice bath for about -10 Cool to ℃.
Blow dry nitrogen gas onto the liquid surface. 2 To this tetrahydrofuran was added 15.06% (1.6N) butyllithium (Foot Mineral Company) 500 in hexane under stirring in a stream of dry nitrogen.
ml over 10 minutes. Cool this near solution to -5 to -10°C. 3 Substantially pure dry tetrahydrofuran
Dissolve 46.4 g of 1-methyl-5-mercaptotetrazole (recrystallized as above) in 200 ml. If it is cloudy, strain the solution and add 5
Cool to ~10°C. 4. Add the cooled solution from step 3 to the butyllithium solution under stirring in a stream of dry nitrogen over 10 minutes.
The temperature must be kept between -5°C and a maximum of +10°C. Precipitates may form. 5. Stir the mixture for 0.5 h at 0°C to +10°C under nitrogen flow. 6. Anhydrous carbon dioxide gas at external temperature (0~10℃) or +
Blow at high speed and with rapid stirring for 15 minutes below 20°C. 7. Collect the white precipitate that forms in a place with low humidity by filtration. Precipitate in tetrahydrofuran approx.
Wash with 75ml. 8 Dissolve this precipitate in 250 ml of water (PH8.5-9.5). A second layer of tetrahydrofuran may be present. This can be removed in a vacuum rotary evaporator (bath 50°C). 9 Adjust the pH of this aqueous solution to 1.6-2.0 with concentrated hydrochloric acid. 10 Extract this acid aqueous solution twice with 250 ml of ethyl acetate each time. Back-extract each 250 ml of ethyl acetate with 100 ml of water. Discard the aqueous extract. Filter the ethyl acetate extract (without the aqueous layer) and combine. 11 Combine the ethyl acetate extracts and concentrate to dryness on a vacuum rotary evaporator (bath 60°C). 12 Boil the crystals in the flask with 300 ml of chloroform for 2 minutes. The hot slurry is vacuum filtered through a heated Buchner To (11 cm-SS-604 paper). Wash the crystals with approximately 75 ml of chloroform at 50°C. The crystals are air-dried for about 3 hours at room temperature and then reduced to about 100-200 meshes. 13 Complete this process exactly as described during step 12.
Treat 100-200 meshes of crystals (hot chloroform removes most of the unreacted 1-methyl-5-mercaptotetrazole). Yield: about 45 to 50 g of crystalline 1-carboxymethyl-5-mercaptotetrazole. These crystals are
It may contain 0.02 to 0.05 mol of 1-methyl-5-mercaptotetrazole. 14 Slurry the crystals from step 13 with 250 ml of ethyl ether for 3-5 minutes at room temperature. Filter this mixture. The insoluble material (0.5-5%) may be a contaminating symmetric mercaptotetrazole ketone with the following tentative structure: CAUTION: This compound is explosive at approximately 205-210°C. 15 Evaporate the ether solution from step 14 to dryness on a vacuum rotary evaporator (bath 50°C). Approximately 0.01
about 42 to 48 crystalline 1-carboxymethyl-5-mercaptotetrazole containing ~0.05 moles of 1-methyl-5-mercaptotetrazole
g is recovered. 16 Dissolve the crystals in 420 ml of absolute ethanol (approximately 100 mg/ml). Warm the solution to 50-60°C. 17 Add 41% in isopropanol to the hot solution in step 16.
Sodium 2-ethylhexanoate (SEH)
Add 310 ml over 10 minutes with very rapid stirring. A crystalline precipitate forms. this mixture
Slurry at 50-60°C for 20 minutes. 18 Heat the mixture through a heated Buchner tube (11 cm - SS - No. 604 paper). Crystals at 50℃
Wash with 75 ml of ethanol. 19 Add 200% ethanol to the ethanol wet crystals from step 18.
Make a ~300ml medium slurry. Pass the slurry through a 200 mesh sieve. Add this slurry under rapid stirring to 50~
Heat to 60℃ for 5 minutes (unreacted 1-methyl-
Sodium 5-mercaptotetrazole is highly soluble in hot ethanol). 20 Heated Buchner Tochu 11cm-SS-604 paper top 50
Collect crystals at ~60°C. This crystal is 75~
Wash with 100ml ethanol and dry at 50-60°C for 24-48 hours. Yield: 40-48 g of 1-carboxymethyl-5-mercaptotetrazole disodium (free of 1-methyl-5-mercaptotetrazole as observed by NMR). Example 3 1-carboxyethyltetrazole-5-thiol A 2-carbethoxyethyl isothiocyanate hydrochloric acid β-alanine ethyl ester (93.6g),
Triethylamine (123.5g) and methylene chloride (400ml) were mixed and cooled to -10°C. Add chloroform to the above solution while keeping the temperature at about -10℃.
Carbon disulfide (46.5 g) dissolved in 150 ml was added during 2 hours. After the addition is complete, keep the temperature at 10℃ for about 10 minutes.
The temperature was raised to . The solution was cooled again to -10 DEG C. and 66.9 g of chloroformic acid in 60 ml of chloroform were added over 40 minutes while stirring. The temperature was allowed to rise to room temperature for 30 minutes and cooled again to 0°C. A further 61.6 g of triethylamine were added at 0° C. and the solution was then stirred for 3 hours at room temperature. Treat this mixture with water, collect the organic phase and 2N
HCl 250ml twice, NaHCO 3 250ml twice, then water 250ml
ml was washed twice. The organic phase was dried over Na 2 SO 4 and the solvent was removed under vacuum to yield 93.7 g of an oil (found to be the desired product). IR and NMR spectra were consistent with the structure. B 1-Carboxyethyltetrazole-5-thiol Sodium azide (29.7 g) was dissolved in 400 ml of water and heated to 60° C. in a nitrogen stream. Skellisolve B
2-carboethoxyethyl isothiocyanate (46.9
g) was added to the heated sodium azide solution. The solution was stirred at about 70-72°C for about 150 minutes and then cooled to 30°C in an ice bath. 50% sodium hydroxide solution was added until the pH was 12. This mixture was heated at 70°C for 40 minutes and then heated to 15°C in an ice bath.
It was cooled to Adjust the PH to 2 using concentrated HCl,
Next, it was extracted with ethyl acetate (150ml x 4). The ethyl acetate extract was washed with water and dried over sodium sulfate. The solvent was evaporated in vacuo and the product was collected as crystals from methylene chloride. 19.5 g of the title product were obtained. Melting point 147-150℃ NMR: DMSO, PPMδ; 2.9, t, 2,
【式】3.4,t,2(CH2 )
IR(KBr)cm-1;2400,3200(OH,SH);1720
(C=0)
実施例 4
1―カルボキシアルキルテトラゾール―5―チ
オールの製造
実施例3における1―カルボキシエチルテトラ
ゾール製造のための操作においてその中で使用さ
れるβ―アラニンエチルエステルの代りに等モル
量の4ないし10個の炭素原子の適当に置換された
アミノ酸エステルを用いて対応する1―カルボキ
シ(C1―C9アルキル)テトラゾール―5―チオ
ール;すなわち
1―カルボキシプロピルテトラゾール―5―チ
オール、1―カルボキシブチルテトラゾール―
5―チオール、1―カルボキシペンチルテトラ
ゾール―5―チオール、1―カルボキシヘキシ
ルテトラゾール―5―チオール、1―カルボキ
シヘプチルテトラゾール―5―チオール、1―
カルボキシオクチルテトラゾール―5―チオー
ル、
ならびに
1―カルボキシノニルテトラゾール―5―チオ
ール、
を得た。
1―カルボキシプロピルテトラゾール―5―チ
オール
NMR:DMSO,PPMδ;1.9―2.4,m,4
[Formula] 3.4, t, 2 (C H 2 ) IR (KBr) cm -1 ; 2400, 3200 (OH, SH); 1720
(C=0) Example 4 Preparation of 1-carboxyalkyltetrazole-5-thiol In place of the β-alanine ethyl ester used therein in the operation for the preparation of 1-carboxyethyltetrazole in Example 3, equimolar the corresponding 1-carboxy(C 1 -C 9 alkyl)tetrazole-5-thiol; i.e. 1-carboxypropyltetrazole-5-thiol, using a suitably substituted amino acid ester of 4 to 10 carbon atoms in an amount of 1-Carboxybutyltetrazole-
5-thiol, 1-carboxypentyltetrazole-5-thiol, 1-carboxyhexyltetrazole-5-thiol, 1-carboxyheptyltetrazole-5-thiol, 1-
Carboxyoctyltetrazole-5-thiol and 1-carboxynonyltetrazole-5-thiol were obtained. 1-carboxypropyltetrazole-5-thiol NMR: DMSO, PPMδ; 1.9-2.4, m, 4
【式】4.3,t(CH2 −N)[Formula] 4.3, t(C H 2 −N)
Claims (1)
有機リチウム化合物で処理して対応するリチオ
誘導体を得; (b) リチオ誘導体を二酸化炭素で処理し、次にこ
れを加水分解して所望の生成物を製造すること
を特徴とする方法。 2 式 (ただし式中nは1ないし9である)の化合物
の製法において、 (a) 式 (ただし式中nは上に定義したとおりであ
り、R100は1ないし6個の炭素原子のアルキ
ル、フエニル、フエニルアルキルまたは置換フ
エニルまたはフエニルアルキルである)のイソ
チオシアネートをアジ化ナトリウムで処理して
式 (ただし式中nおよびR100は上に定義したと
おりである)のチオールエステルを得; (b) チオールエステルを加水分解して所望のチオ
ール酸を製造する ことを特徴とする方法。[Claims] 1 formula (a) Treating 1-methyl-5-mercaptotetrazole with an organolithium compound to obtain the corresponding lithio derivative; (b) Treating the lithio derivative with carbon dioxide, which is then hydrolyzed. A process characterized in that the desired product is produced by: 2 formulas (wherein n is 1 to 9) In the method for producing a compound of formula (a) (wherein n is as defined above and R 100 is alkyl, phenyl, phenylalkyl or substituted phenyl or phenylalkyl of 1 to 6 carbon atoms) with sodium azide. process and expression (b) hydrolyzing the thiol ester to produce the desired thiol acid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50299174A | 1974-09-03 | 1974-09-03 | |
US502991 | 1974-09-03 | ||
US590971 | 1990-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60222470A JPS60222470A (en) | 1985-11-07 |
JPS6348870B2 true JPS6348870B2 (en) | 1988-09-30 |
Family
ID=24000311
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60046699A Granted JPS60222489A (en) | 1974-09-03 | 1985-03-11 | Manufacture of 7-aminocephem compound |
JP60046700A Granted JPS60222470A (en) | 1974-09-03 | 1985-03-11 | Manufacture of 1-carboxyalkyl-5-mercaptotetrazole |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60046699A Granted JPS60222489A (en) | 1974-09-03 | 1985-03-11 | Manufacture of 7-aminocephem compound |
Country Status (14)
Country | Link |
---|---|
JP (2) | JPS60222489A (en) |
AT (3) | AT349140B (en) |
AU (1) | AU503240B2 (en) |
BE (1) | BE832725A (en) |
BG (1) | BG27753A3 (en) |
CH (1) | CH623330A5 (en) |
CS (3) | CS202056B2 (en) |
CY (1) | CY1120A (en) |
GB (1) | GB1525626A (en) |
HK (1) | HK45081A (en) |
KE (1) | KE3157A (en) |
MY (1) | MY8200111A (en) |
SU (2) | SU691094A3 (en) |
ZA (1) | ZA755543B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4093723A (en) | 1976-05-19 | 1978-06-06 | Smithkline Corporation | 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins |
US4082912A (en) | 1976-06-30 | 1978-04-04 | Bristol-Myers Company | Certain 7-acylamido-3-(2-carboxyalkyl-2,3-dihydro-s-triazolo[4,3-b]pyridazin-3-on-6-ylmethyl)-3-cephem-4-carboxylic acids their salts and easily hydrolyzed esters |
US4066762A (en) * | 1976-07-12 | 1978-01-03 | Smithkline Corporation | Derivatives of 7-(2-substituted-2-hydroxyiminoacetamido)-3-(1-substituted tetrazol-5-ylthiomethyl-3-cephem-4-carboxylic acid |
US4278670A (en) * | 1976-07-12 | 1981-07-14 | Smithkline Corporation | 7-Alpha-oxyiminoacylcephalosporins |
US4117125A (en) | 1977-06-24 | 1978-09-26 | Smithkline Corporation | 7-Acylamino-3-[1-[2-(carboxymethylamino]ethyl) tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids |
DK225179A (en) | 1978-06-22 | 1979-12-23 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR PREPARING CEPHALOSPORINE DERIVATIVES |
JPH01300075A (en) * | 1988-05-25 | 1989-12-04 | Tokyo Seimitsu Hatsujo Kk | Fluid pouring device |
-
1975
- 1975-08-25 BE BE159447A patent/BE832725A/en not_active IP Right Cessation
- 1975-08-29 ZA ZA00755543A patent/ZA755543B/en unknown
- 1975-09-01 BG BG7736219A patent/BG27753A3/en active Active
- 1975-09-02 CH CH1134575A patent/CH623330A5/en not_active IP Right Cessation
- 1975-09-02 AU AU84469/75A patent/AU503240B2/en not_active Expired
- 1975-09-02 GB GB36079/75A patent/GB1525626A/en not_active Expired
- 1975-09-02 AT AT676475A patent/AT349140B/en not_active IP Right Cessation
- 1975-09-02 CY CY1120A patent/CY1120A/en unknown
- 1975-09-03 SU SU752170664A patent/SU691094A3/en active
- 1975-09-03 CS CS755997A patent/CS202056B2/en unknown
-
1976
- 1976-08-10 SU SU762388313A patent/SU685157A3/en active
-
1977
- 1977-06-07 CS CS773751A patent/CS202058B2/en unknown
- 1977-06-07 CS CS773750A patent/CS202057B2/en unknown
- 1977-10-10 AT AT723377A patent/AT348520B/en not_active IP Right Cessation
-
1978
- 1978-04-24 AT AT294178A patent/AT349638B/en not_active IP Right Cessation
-
1981
- 1981-08-25 KE KE3157A patent/KE3157A/en unknown
- 1981-09-03 HK HK450/81A patent/HK45081A/en unknown
-
1982
- 1982-12-30 MY MY111/82A patent/MY8200111A/en unknown
-
1985
- 1985-03-11 JP JP60046699A patent/JPS60222489A/en active Granted
- 1985-03-11 JP JP60046700A patent/JPS60222470A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
ZA755543B (en) | 1976-07-28 |
AU8446975A (en) | 1977-03-10 |
CS202056B2 (en) | 1980-12-31 |
CH623330A5 (en) | 1981-05-29 |
JPS6135200B2 (en) | 1986-08-12 |
SU685157A3 (en) | 1979-09-05 |
MY8200111A (en) | 1982-12-31 |
AT349140B (en) | 1979-03-26 |
AT348520B (en) | 1979-02-26 |
ATA294178A (en) | 1978-09-15 |
ATA676475A (en) | 1978-08-15 |
AT349638B (en) | 1979-04-10 |
SU691094A3 (en) | 1979-10-05 |
JPS60222489A (en) | 1985-11-07 |
CY1120A (en) | 1981-12-04 |
CS202057B2 (en) | 1980-12-31 |
JPS60222470A (en) | 1985-11-07 |
GB1525626A (en) | 1978-09-20 |
BE832725A (en) | 1976-02-25 |
KE3157A (en) | 1981-09-18 |
HK45081A (en) | 1981-09-11 |
ATA723377A (en) | 1978-07-15 |
CS202058B2 (en) | 1980-12-31 |
AU503240B2 (en) | 1979-08-30 |
BG27753A3 (en) | 1979-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ212541A (en) | 4-(4-(dimethylamino)-1-(4'-fluorophenyl)-1- hydroxybutyl)-3- (hydroxymethyl)-benzonitrile | |
CA2431976C (en) | Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, their production and use | |
JPS6348870B2 (en) | ||
JPS5940380B2 (en) | Mixed halogenated magnesium compound and its production method | |
KR20040111490A (en) | Novel form of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine | |
JPH08506332A (en) | Process for producing tetrazole-5-carboxylic acid derivative | |
SU679135A3 (en) | Method of producing aminopropanol derivatives or salts thereof | |
WO1994015904A1 (en) | Novel process and intermediates for the preparation of prodrugs | |
JPH01110678A (en) | Trisodium salt of 2,4,6-trisodium mercapto-s-triazine-9 hydrate and manufacture | |
JPS639507B2 (en) | ||
JPH1087683A (en) | Production of mixed glucosamine salt | |
JPS60204742A (en) | Preparation of tetrafluoro-4-hydroxybenzoic acid | |
FI63943B (en) | VID FRAMSTAELLNING AV 7-ACYLAMIDO-3- (1-CARBOXY-LAEGRE-ALKYL-TETRAZOLE-5-YLTHOMETHYL) -3-CEFEM-4-CARBOXYLSYROR OR DERAS SALTER SAOSOM MELLANPRODUKTER ANVAENDBARA FOERENAR | |
US3928334A (en) | Process for the production of cefamandole | |
JPH078853B2 (en) | Method for producing dopamine derivative | |
RU1473300C (en) | Method of synthesis of 4-benzoylamino-3-oxotetrahydrothiophene | |
Perkin et al. | LXXVII.—Contributions from the Laboratories of the Heriot Watt College, Edinburgh. Synthesis of homogues of pentanetetracarboxylic acid and of pimelic acid | |
US2522178A (en) | 16-keto-estrogens | |
JPS5840541B2 (en) | 3-Tikan-2(1H) Pyridone-6-Carbonsanno Seihou | |
SU554813A3 (en) | The method of obtaining derivatives of tetrazole or their salts | |
JPS5835518B2 (en) | (E)-5-) Beta-thikanvinyl)-2- Thienylsakusannoseizohouhou | |
JPS6210500B2 (en) | ||
JPS58144374A (en) | Indazoleacetic acid derivative and its preparation | |
JPS5823681A (en) | Preparation of 1-substituted-5-mercapto-tetrazole | |
JPS6215073B2 (en) |